OR Royalties Inc. Declares Quarterly Dividend of $0.07 (NYSE:OR)

OR Royalties Inc. (NYSE:OR) announced a quarterly dividend on Wednesday, August 5th. Shareholders of record on Wednesday, September 30th will be given a dividend of 0.065 per share by the basic materials company on Thursday, October 15th. This represents a c) annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, September 30th.

OR Royalties has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 1 consecutive years. OR Royalties has a payout ratio of 33.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect OR Royalties to earn $1.26 per share next year, which means the company should continue to be able to cover its $0.25 annual dividend with an expected future payout ratio of 19.8%.

OR Royalties Trading Down 0.1%

NYSE OR traded down $0.04 on Thursday, reaching $32.20. The company’s stock had a trading volume of 453,228 shares, compared to its average volume of 1,181,004. OR Royalties has a 52 week low of $27.54 and a 52 week high of $48.06. The firm has a market cap of $6.03 billion, a PE ratio of 24.07 and a beta of 0.75. The business has a 50-day moving average price of $31.86 and a 200 day moving average price of $37.35.

OR Royalties (NYSE:OR) last issued its earnings results on Wednesday, August 5th. The basic materials company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.The business had revenue of $97.82 million during the quarter, compared to analysts’ expectations of $97.93 million. Analysts anticipate that OR Royalties will post 1.27 earnings per share for the current fiscal year.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.